Will the targeted drug axitinib/axitinib grow wildly once the drug is discontinued?

Axitinib/Axitinib is a targeted drug mainly used to treat advanced renal cell carcinoma. It blocks the blood supply and growth of tumors by inhibiting the vascular endothelial growth factor receptor (VEGFR). In clinical application, many patients have achieved a certain degree of tumor control after receiving axitinib treatment, but once the drug is discontinued, the situation faced by the patients is complicated.

First, understanding the mechanism of action of axitinib is important to predict response after discontinuation of the drug. This drug achieves the effect of controlling tumors by inhibiting the proliferation and angiogenesis of tumor cells. If a patient's tumor is effectively controlled while taking axitinib, tumor regrowth may occur after discontinuation of the drug, because tumor cells may restart proliferation in the absence of inhibitory signals.

Secondly, the biological characteristics of the tumor, individual differences among patients, and previous treatment history will all affect the response after drug withdrawal. Some patients may be able to maintain a longer period of progression-free survival after stopping the drug because the characteristics of the tumor make it less dependent on external factors; while other patients may experience rapid tumor recurrence within a short period of time. Therefore, it cannot be generally said that drug withdrawal will inevitably lead to tumor growth.

In addition, clinical studies have shown that after stopping axitinib, the patient's therapeutic effect can be guaranteed to a certain extent through regular monitoring and timely intervention. Some doctors recommend closely observing changes in the patient's condition after stopping the drug and deciding whether to restart treatment or use other therapies based on the specific situation.

Finally, patients should fully communicate with their doctors when discontinuing medication to understand the monitoring plan and possible risks after discontinuation. At the same time, maintaining a healthy lifestyle and a good mentality can also help improve the body's resistance and reduce the risk of tumor recurrence.

References:https://www.plainlanguagesummaries.com/plain-language-summary-looking-at-how-long-side-effects-last-after-stopping-axitinib-treatment-in-people-with-advanced-renal-cell-carcinoma/